What Tests Do Anti-Aging Doctors Use to Prove Patient Protocols Work? A Practitioner's Guide

Anti-aging and longevity doctors prove that a protocol works by retesting the same biomarker before and after an intervention, rather than relying on symptom reports alone. A biomarker used as the retest of choice by functional medicine and longevity practitioners needs to measure active immune-driven inflammation through IgG glycosylation (sugar structures attached to antibodies) and shift within months of a real biological change. This article answers the questions practitioners ask most often when deciding which tests belong in a protocol-validation workflow, and how to build retesting into patient care without adding clinical noise. 

For a deeper look at how this fits into clinical and corporate wellness practice, see GlycanAge for Healthcare Providers, Functional Medicine Clinics & Corporate Wellness Programs.

What test do longevity doctors use to prove a protocol is working?

Longevity and functional medicine doctors increasingly use GlycanAge, a test that measures biological age through IgG glycosylation, the sugar patterns attached to antibodies that shift with chronic inflammation and immune function. Unlike a one-time genetic readout, glycan results are dynamic: they change in response to treatment, which is what makes them useful for tracking whether an intervention actually worked rather than just confirming a fixed genetic baseline. Practitioners order the test at intake, before starting a new protocol, so the result functions as a true pre-intervention baseline, then retest at an interval matched to the intervention type.

How is this different from an epigenetic clock or a DNA test?

DNA tests and biological age tests measure fundamentally different things, which is why they can produce different numbers for the same person on the same day. A DNA test reveals fixed genetic potential and does not change when a patient's health changes, while GlycanAge tracks current, active immune-driven inflammation and responds to treatment. GlycanAge is designed for high test-retest consistency, so a change in a patient's result is more likely to reflect a real biological shift than measurement noise. That distinction determines what each tool is fit for in a practice: DNA and epigenetic tests for a one-time or slow-changing baseline, GlycanAge for tracking whether this quarter's protocol is actually working. If a patient has already run a DNA panel, GlycanAge is the logical next test rather than a duplicate, since it answers a different clinical question.

"We either use things that measure metabolites or enzyme concentrations, which change extremely quickly, or we look at the genes, which don't change at all. We're missing the intermediate phenotype between these day-to-day altering molecules and genes that don't change, and that's where glycans come in."

— Prof. Gordan Lauc, Professor of Biochemistry and Molecular Biology, University of Zagreb, and Co-Founder & Chief Scientific Officer, GlycanAge

Where does biological age testing fit in the patient intake process?

Biological age testing fits earliest in the intake process, ordered before any new protocol begins, so the result establishes a genuine pre-intervention baseline rather than a mid-treatment snapshot. Practitioners are encouraged to gather medication history, current therapies, and lifestyle habits alongside the result, because glycans can reflect the effects of hormone replacement and other active treatments already underway. This baseline-and-context approach means the clinician is not reading the number in isolation but against the patient's actual treatment history. Practitioners can strengthen this further by pairing each GlycanAge order with a short intake questionnaire covering current medications and lifestyle factors, giving the interpretation call full context from the outset.

How soon can I retest a patient after starting a new protocol?

Retest timing depends entirely on what kind of protocol you started. Pharmaceutical and HRT-based protocols, including hormone titration and peptide regimens, typically produce measurable glycan shifts within months, so retesting in that window allows for early assessment and dose adjustment. Lifestyle-based protocols, such as nutrition changes, exercise programs, or stress management, move more gradually, and 6 to 12 months is the window that captures a genuine, sustained trend rather than short-term noise. This two-speed retest model matters most in the interventions functional medicine and longevity practices already run: HRT titration for perimenopausal and menopausal patients, peptide and hormone protocols in longevity clinics, and structured nutrition or stress-reduction programs in executive health work. You can set the retest date at the same visit you establish the baseline, so the patient has a fixed point on the calendar rather than an open-ended "check back sometime."

Can this actually prove HRT is working, or just that symptoms improved?

A retested biological age result can show a systemic, measurable shift that goes beyond symptom relief.

"With optimized hormone replacement, I've seen patients drop 20 to 25 years off their GlycanAge. This isn't just about relieving menopausal symptoms. It's about showing measurable improvements in biological age and inflammation. For the first time, we can prove the systemic benefits of HRT with objective data."

 — Dr. Joseph Raffaele, MD, Founder, Raffaele Medical, New York City 

That kind of shift, retested against a patient's own baseline rather than a population average, is the model to replicate with every HRT patient: use the pre-treatment number as the fixed reference point in every follow-up conversation, so improvement is always anchored to where that individual started, with the understanding that the degree of change varies by patient.

Does this replace the blood panels my practice already runs?

No. GlycanAge is designed to sit on top of existing blood work, not replace it, adding a dedicated aging and inflammation signal that most standard panels do not carry. Understanding why standard bloodwork misses chronic inflammation helps clinicians see why adding a glycan-based test provides a more comprehensive view of a patient's health. It gives clinicians an additional layer for baselining and retesting patients through hormone, peptide, or lifestyle protocols, without duplicating what a metabolic or lipid panel already measures. This makes it a low-friction addition to a practice's existing workflow: you are not swapping out a panel, you are adding the one signal it was missing. You can slot the test into whatever panel schedule you already run at intake and at defined follow-up intervals.

Which patients in my practice are the best fit for this kind of testing?

Patients already investing in how they look and age, through skincare, aesthetic procedures, or hormone therapy, are typically primed to engage with a biomarker that shows what is happening beneath the surface. In clinical use, new patients typically baseline close to their chronological age, and once they start a structured program, that number begins to move. Results also tend to hold steady between tests when nothing has changed, which is what lets a clinician trust that a shift, when it happens, reflects the protocol rather than noise, and adjust therapy if the number does not move as expected. 

.

How do I present the result to a patient without it sounding like a diagnosis?

Present the result as an objective, independent reference point that sits outside the intervention itself, not as a verdict on the patient's health. This "objective referee" framing does real clinical work: the patient is not asked to trust the treatment on faith, and the practice is not the only voice validating its own protocol, because the biomarker measures whether the biology actually shifted. Walk the patient through their glycan index pattern and connect it back to the specific protocol they are on, rather than handing over the report as an unexplained document. GlycanAge is a biomarker for tracking and interpretation, not a diagnostic tool, so frame every conversation around what changed and what to monitor next, not around disease risk or prediction.

Preventive care in a longevity practice lives or dies on proof, not intention. A practice that can show a patient a biological age reading before an HRT protocol, and a measurably lower one after, offers something a supplement recommendation or a single aesthetic procedure cannot: a repeatable signal that the intervention worked at the level of immune function and chronic inflammation, not just at the level of how the patient feels. 

If you're ready to build this into your protocol library, visit the Healthcare Providers page to explore partner onboarding, starter packs, and the 1:1 result interpretation support built for clinical teams. 

Give your patients an objective way to see whether their protocol is working, not just whether it feels like it is. 

Explore Partnership Options for Providers →

External sources

• https://pmc.ncbi.nlm.nih.gov/articles/PMC4049143/ —  Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci. 2014;69(7):779-789. 

• https://pmc.ncbi.nlm.nih.gov/articles/PMC8236401/ — Greto VL, Cvetko A, Štambuk T, Dempster NJ, Kifer D, Deris H, et al. Extensive weight loss reduces glycan age by altering IgG N-glycosylation. Int J Obes (Lond). 2021;45(7):1521-1531.